TRAF5 and colorectal carcinoma: The combination of a novel pan‐caspase inhibitor, IDN‐7314, with 5‐FU, showed promising results in inhibiting CRC cell growth.[145] In CRC, the overexpression of miR‐29b‐3p was found to be involved in resistance to 5‐FU‐induced necroptosis by targeting TRAF5.[146] In ESCC, high expression of STAT3 was found to correlate with better survival and enhanced sensitivity to concurrent chemoradiotherapy.